Abstract：Objective: To study the efficacy of compound Zaofan pills combined with cyclosporine A and testosterone undecanoate in the treatment of non-severe aplastic anemia (NSAA). Methods: A retrospective analysis was performed on 80 patients with NSAA admitted to the hospital from January 2020 to January 2023. According to the treatment methods, they were divided into study group (40 cases) and control group (40 cases). The study group was treated with compound Zaofan pills combined with cyclosporine A and testosterone undecanoate, and the control group was treated with cyclosporine A and stanazolol. The lymphocyte subsets (CD4+, CD8+), white blood cell count, platelet count, hemoglobin level before and after treatment, liver function indexes [serum alkaline phosphatase (ALP), glutamyltransferase (GGT), aspartate aminotransferase (AST), alanine aminotransferase (ALT)], total effective rate, side effects (toxic side effects, liver function) were compared between the two groups. Results: There were no significant differences in CD4+, CD8+, white blood cell count, platelet count and hemoglobin level between the two groups before treatment (P>0.05). Compared with before treatment, CD4+, white blood cell count, platelet count and hemoglobin level were higher in the two groups after treatment, and CD8+ was lower, the difference was statistically significant (P<0.05). Compared with the control group, the CD4+, white blood cell count, platelet count, hemoglobin level and total effective rate of the study group were higher, and the CD8+, ALP, GGT, AST, ALT levels and the incidence of toxic side effects and abnormal liver function were lower, the differences were statistically significant (P<0.05). Conclusion: Compound Zaofan pill combined with cyclosporine A and testosterone undecanoate is effective in the treatment of patients with NSAA, which can enhance the cellular immune function, improve white blood cell count, platelet count and hemoglobin level, and reduce the degree of liver damage, with few side effects and high safety.
卫淑娟, 王晶, 吕文艳, 李晶晶. 以环孢素A为主的复方用药方案治疗非重型再生障碍性贫血疗效分析[J]. 河北医学, 2023, 29(10): 1730-1734.
WEI Shujuan, WANG Jing, LU Wenyan, et al. Analysis of the Efficacy of Cyclosporin A-based Compound Medication Regimen in the Treatment of Non-Severe Aplastic Anemia. HeBei Med, 2023, 29(10): 1730-1734.
[1] 郑文献.复方皂矾丸联合左旋咪唑+雄激素治疗非重型再生障碍性贫血患儿的临床疗效[J].内蒙古中医药,2022,41(1):41-42. [2] Xinyu T,Ruirong X,Yan W,et al. TERC haploid cell reprogramming:a novel therapeutic strategy for aplastic anemia[J].Mol Med,2023,29(1):94. [3] 张之南,沈悌.血液病诊断及疗效标准[M].第3版.北京:科学出版社,2007.20-21. [4] 王晓利,张辉果.复方皂矾丸联合司坦唑醇片治疗小儿再生障碍性贫血的临床观察[J].中国民间疗法,2019,27(4):61-62. [5] 徐淑梅,安琪,王磊.国内复方皂矾丸治疗慢性再生障碍性贫血效果的Meta分析[J].河南医学研究,2018,27(24):4422-4426. [6] Liu C X;Song L;Zhang L,et al.Prognostic factors of cyclosporine A combined with androgen in the treatment of transfusion dependent non-severe aplastic anemia[J].Zhonghua xue ye xue za zhi,2020,41(3):528-535. [7] Yuan Y,Zengwei T,Yuzhou H,et al.Sirolimus versus cyclosporine A in patients with primary acquired pure red cell aplasia:a prospective cohort study[J].Blood Cancer,2023,13(1):74. [8] YU C,Qiang Z,Fei H,et al.The efficacy of eltrombopag plus cyclosporine A in patients with transfusion-dependent non-severe aplastic anemia:a retrospective study from single center[J].Zhonghua nei ke za zhi,2022,61(4):725-732. [9] XiaoTian Z,YaNan Z,JingJing Z,et al.The efficacy and safety of cyclosporine A plus androgen versus androgen alone for adult patients with non-severe aplastic anemia in China:a meta-analysis of randomized controlled trials[J].Hematology (Amsterdam,Netherlands),2022,27(1):261-267. [10] 张稚淳,张晓波,丁皓,等.复方皂矾丸或联合西药治疗血液病疗效和安全性的Meta分析[J].北京中医药大学学报,2018,41(10):873-880.
2023, Vol. 29 
冀公网安备13080202000677号